Cytogenetic study of a pulmonary sclerosing hemangioma

Abstract Pulmonary sclerosing hemangioma (PSH) is an uncommon benign tumor that presents as a solitary asymptomatic and slow-growing nodule. It occurs in both young and old persons; peak incidence is in the fifth decade. Both sexes are affected by this tumor, but women more frequently than men. On h...

Full description

Saved in:
Bibliographic Details
Published in:Cancer genetics and cytogenetics 2009-11, Vol.195 (1), p.80-84
Main Authors: Pareja, María J, Vargas, María T, Sánchez, Ana, Ibáñez, José, González-Cámpora, Ricardo
Format: Article
Language:English
Subjects:
Female
Hematology, Oncology and Palliative Medicine
Humans
In Situ Hybridization, Fluorescence
Karyotyping
Medical Education
Middle Aged
Pulmonary Sclerosing Hemangioma - genetics
Pulmonary Sclerosing Hemangioma - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Pulmonary sclerosing hemangioma (PSH) is an uncommon benign tumor that presents as a solitary asymptomatic and slow-growing nodule. It occurs in both young and old persons; peak incidence is in the fifth decade. Both sexes are affected by this tumor, but women more frequently than men. On histological examination, PSH shows prominent sclerotization and vascularization of the tissue. Recent studies conclude that PSH derives from type II pneumocytes, but the potential for progression and histogenesis remains controversial. We report a case of pulmonary sclerosing hemangioma in a 61-year-old woman with a neoplastic node 1 cm in diameter. The karyotype was 46,XX,t(8;18),der(14;15),+14 in all the cells analyzed. PTEN (10q23) and IgH (14q32) probes were analyzed in interphase nuclei and paraffin-embedded tissues of tumor cells. These chromosome abnormalities could provide information about the relationship of genetic changes to the biological properties of sclerosing hemangioma tumors.
ISSN:0165-4608
1873-4456
DOI:10.1016/j.cancergencyto.2008.02.017